OVERVIEW

Treatment options for relapsed/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 2nd Midwest Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned . This activity will engage an interprofessional audience of learners with important updates in hematologic oncology that are provided at the annual Transplantation and Cellular Therapy (TCT) meeting organized in February 2022, and at the American Society of Hematology (ASH) in December 2021. As an added benefit, a half-day pre-conference entitled Women in Cell Therapy will be provided.

TARGET AUDIENCE

This CE program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.

LEARNING OBJECTIVES

Following participation in this activity, learners will:

• Discuss individualized treatment options for high-risk patients with diffuse large B-cell lymphoma (DLBCL), Hodgkins lymphoma (HL), non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
• Include autologous or allogeneic HCT and/or CAR T-cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.
• Manage potential complications resulting from autologous or allogeneic HCT and/or CAR T-cell therapy.
• Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR T-cell therapy for patients with various refractory (advanced) hematologic malignancies.
• Discuss the role of gender in the management and treatment of various hematologic conditions

ACCREDITATION

Rush University Medical Center designates this live activity for a maximum of Nine and a Quarter (9.25) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their
participation in the activity.

For more informations please visit the official event page.